Immunotherapy and radiation for early-stage nasal-type lymphoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage (stage I or II) nasal-type NK/T-cell lymphoma.
- You have not received any previous treatment for your lymphoma.
- You are at least 18 years old.
- You are in generally good health (ECOG performance status 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for early-stage NK/T-cell lymphoma of the nose or throat. The treatment is adjusted based on how well the disease responds, aiming to be more effective and reduce side effects.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Hear when a new Natural Killer/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.